NCT03600441 2025-04-10FORERUNNERXynomic Pharmaceuticals, Inc.Phase 2 Active not recruiting139 enrolled
NCT03934567 2025-04-10A Multi-Center Phase 2 Study to Evaluate Efficacy and Safety of Oral Abexinostat as Monotherapy in Patients With Relapsed or Refractory Follicular LymphomaXynomic Pharmaceuticals, Inc.Phase 2 Active not recruiting87 enrolled